Yan Huimin, Lu Jia, Wang Jiabao, Chen Lu, Wang Yu, Li Lin, Miao Lin, Zhang Han
State Key Laboratory of Component-based Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, China.
Institute of Traditional Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, China.
Front Pharmacol. 2021 Oct 19;12:730567. doi: 10.3389/fphar.2021.730567. eCollection 2021.
Xuanfei Baidu decoction (XFBD), a traditional Chinese medicine formulation, was designed and successfully applied for COVID-19 disease treatment in China, while the mechanism is still not clear. To evaluate the protective effect of XFBD on immunosuppression in cyclophosphamide (CY)-treated mice, XFBD was orally administrated, the body weight was measured, and the immune organ index was calculated. HE staining was performed to analyze the pathological structures of the liver, spleen, and thymus. The levels of cytokines and immunoglobulin in the serum and spleen were evaluated by ELISA and RT-PCR. Splenic lymphocytes were isolated, and LPS-stimulated cell proliferation and the number of CD4 and CD8 T lymphocytes were evaluated. XFBD significantly suppressed body weight loss and increased the indices of spleen and thymus. The pathological alteration was much improved after XFBD administration. The reductions of TNF-α, IFN-γ, IgG, and IgM levels in serum and IL-2, IL-4, and IL-6 expressions in the spleen were all significantly alleviated by XFBD. Splenic lymphocyte proliferation in response to LPS was further enhanced after treatment with XFBD. The reduction of CD4 and CD8 T lymphocytes in CY-treated mice was also highly increased in XFBD groups. Our findings suggested that XFBD played a crucial role in protection against immunosuppression in CY-treated mice and could be a potential candidate for immune modification and therapy.
宣肺败毒汤(XFBD)是一种中药配方,在中国已被设计并成功应用于治疗新冠肺炎,但作用机制仍不清楚。为了评估宣肺败毒汤对环磷酰胺(CY)处理小鼠免疫抑制的保护作用,给予小鼠口服宣肺败毒汤,测量体重并计算免疫器官指数。进行苏木精-伊红(HE)染色以分析肝脏、脾脏和胸腺的病理结构。通过酶联免疫吸附测定(ELISA)和逆转录-聚合酶链反应(RT-PCR)评估血清和脾脏中细胞因子和免疫球蛋白的水平。分离脾淋巴细胞,评估脂多糖(LPS)刺激的细胞增殖以及CD4和CD8 T淋巴细胞的数量。宣肺败毒汤显著抑制体重减轻,增加脾脏和胸腺指数。给予宣肺败毒汤后病理改变有很大改善。宣肺败毒汤显著减轻血清中肿瘤坏死因子-α(TNF-α)、干扰素-γ(IFN-γ)、免疫球蛋白G(IgG)和免疫球蛋白M(IgM)水平的降低以及脾脏中白细胞介素-2(IL-2)、白细胞介素-4(IL-4)和白细胞介素-6(IL-6)表达的降低。用宣肺败毒汤处理后,脾淋巴细胞对LPS的增殖反应进一步增强。宣肺败毒汤组中环磷酰胺处理小鼠CD4和CD8 T淋巴细胞数量的减少也显著增加。我们的研究结果表明,宣肺败毒汤在保护环磷酰胺处理的小鼠免受免疫抑制方面起关键作用,可能是免疫调节和治疗的潜在候选药物。